☆ 4.3 Editorial Material

Intrinsic molecular subtypes of HER2+breast cancer

ONCOTARGET (2017)

Journal

ONCOTARGET

Volume 8, Issue 43, Pages 73362-73363

Publisher

IMPACT JOURNALS LLC

DOI: 10.18632/oncotarget.20629

Keywords

HER2 blockade; breast cancer; HER2-positive; intrinsic subtype; HER2-enriched

Categories

Oncology Cell Biology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Review Biochemistry & Molecular Biology

Role of Intrinsic Subtype Analysis with PAM50 in Hormone Receptors Positive HER2 Negative Metastatic Breast Cancer: A Systematic Review

Fabio Canino, Federico Piacentini, Claudia Omarini, Angela Toss, Monica Barbolini, Patrizia Vici, Massimo Dominici, Luca Moscetti

Summary: This systematic review analyzed the potential correlations between intrinsic subtype, treatment efficacy, and patient outcome in HR+/HER2- mBC. It found that non-luminal subtypes were more common in endocrine-resistant patients and metastatic sites, had less benefit from endocrine therapy, and worse prognosis. HER2-enriched subtypes behaved similarly to HER2+ tumors and showed benefit from anti-HER2 agents, while basal-like subtypes were more sensitive to chemotherapy. Currently, intrinsic subtype does not play a decisive role in treatment choice but has potential prognostic and predictive value.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Add to Collection

Article Oncology

Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancer

Maria Vittoria Dieci, Pierfranco Conte, Giancarlo Bisagni, Stefania Bartolini, Antonio Frassoldati, Daniele Generali, Federico Piacentini, Gaia Griguolo, Enrico Tagliafico, Fara Braso Maristany, Nuria Chic, Laia Pare, Federica Miglietta, Roberto Vicini, Roberto D'Amico, Sara Balduzzi, Aleix Prat, Valentina Guarneri

Summary: The integration of intrinsic molecular subtypes with stage or HER2DX risk score can predict site-specific metastatic risk in HER2-positive breast cancer, potentially impacting personalized surveillance and preventing site-specific recurrence in clinical trials.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2023)

Add to Collection

Review Oncology

Meta-Analysis of HER2-Enriched Subtype Predicting the Pathological Complete Response Within HER2-Positive Breast Cancer in Patients Who Received Neoadjuvant Treatment

Guoshuang Shen, Fuxing Zhao, Xingfa Huo, Dengfeng Ren, Feng Du, Fangchao Zheng, Jiuda Zhao

Summary: The HER2-enriched subtype is a strong predictor of pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant treatment, especially when HER2-targeted agents are used, regardless of the specific agents or additional therapies employed.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Oncology

Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer

Paolo Nuciforo, John Townend, Martine J. Piccart, Shona Fielding, Panagiota Gkolfi, Sarra El-Abed, Evandro de Azambuja, Gustavo Werutsky, Judith Bliss, Volker Moebus, Marco Colleoni, Alvaro Moreno Aspitia, Henry Gomez, Andrea Gombos, Maria A. Coccia-Portugal, Ling-Ming Tseng, Georg Kunz, Guillermo Lerzo, Joohyuk Sohn, Vladimir Semiglazov, Cristina Saura, Judith Kroep, Antonella Ferro, David Cameron, Richard Gelber, Jens Huober, Serena Di Cosimo

Summary: Dual anti-HER2-targeted therapy combined with chemotherapy significantly improves the rate of pathological complete response (pCR) in breast cancer patients. However, limited data exist on the long-term impact of the increased pCR on survival.

EUROPEAN JOURNAL OF CANCER (2023)

Add to Collection

Article Multidisciplinary Sciences

Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance

Rosalynd Upton, Allison Banuelos, Dongdong Feng, Tanuka Biswas, Kevin Kao, Kelly McKenna, Stephen Willingham, Po Yi Ho, Benyamin Rosental, Michal Caspi Tal, Tal Raveh, Jens-Peter Volkmer, Mark D. Pegram, Irving L. Weissman

Summary: Trastuzumab, a targeted anti-HER2 monoclonal antibody, is effective for early-stage HER2(+) breast cancer but resistance often develops in advanced-stage patients. Combining trastuzumab with anti-CD47 immunotherapy shows promising results in inhibiting the growth of ADCC-tolerant HER2(+) breast cancers.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)

Add to Collection

Article Multidisciplinary Sciences

Biomarker dynamics affecting neoadjuvant therapy response and outcome of HER2-positive breast cancer subtype

Sandra Orru, Emanuele Pascariello, Barbara Pes, Vincenzo Rallo, Raffaele Barbara, Marta Muntoni, Francesca Notari, Gianfranco Fancello, Cristina Mocci, Maria Rosaria Muroni, Paolo Cossu-Rocca, Andrea Angius, Maria Rosaria De Miglio

Summary: In this study, the predictive and prognostic role of HER2 protein/gene expression levels combined with clinico-pathologic features in HER2+ breast cancer patients receiving trastuzumab-based neoadjuvant chemotherapy was evaluated. The study found that a high tumoral pathological complete response rate is associated with a high percentage of infiltrating immune cells and right-sided tumors, which reduce distant metastasis and improve survival. HER2 protein expression levels and tumor laterality emerge as strong predictors of tumoral pathological complete response.

SCIENTIFIC REPORTS (2023)

Add to Collection

Article Multidisciplinary Sciences

Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer

Anna Adam-Artigues, Enrique J. Arenas, Alex Martinez-Sabadell, Fara Braso-Maristany, Raimundo Cervera, Eduardo Tormo, Cristina Hernando, Maria Teresa Martinez, Juan Carbonell-Asins, Soraya Simon, Jesus Poveda, Santiago Moragon, Sandra Zazo, Debora Martinez, Ana Rovira, Octavio Burgues, Federico Rojo, Joan Albanell, Begona Bermejo, Ana Lluch, Aleix Prat, Joaquin Arribas, Pilar Eroles, Juan Miguel Cejalvo

Summary: AXL overexpression is identified as an essential mechanism of trastuzumab resistance in HER2-positive breast cancer, and targeting AXL can restore trastuzumab response. AXL may serve as a predictive biomarker for prognosis in HER2-positive breast cancer patients. The study emphasizes the importance of targeting AXL in combination with anti-HER2 drugs to overcome resistance.

SCIENCE ADVANCES (2022)

Add to Collection

Article Multidisciplinary Sciences

Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer

Nindo B. Punturi, Sinem Seker, Vaishnavi Devarakonda, Aloran Mazumder, Rashi Kalra, Ching Hui Chen, Shunqiang Li, Tina Primeau, Matthew J. Ellis, Shyam M. Kavuri, Svasti Haricharan

Summary: Resistance to endocrine treatment in ER+ breast cancer patients is linked to activation of HER2 due to loss of mismatch repair, and inhibiting HER2 restores sensitivity to treatment. Loss of MutL and upregulation of HER2 are associated with sensitivity to HER inhibitors in ER+/HER2(-) patients.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Medicine, General & Internal

HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer

Milana A. Bergamino, Elena Lopez-Knowles, Gabriele Morani, Holly Tovey, Lucy Kilburn, Eugene F. Schuster, Anastasia Alataki, Margaret Hills, Hui Xiao, Chris Holcombe, Anthony Skene, John F. Robertson, Ian E. Smith, Judith M. Bliss, Mitch Dowsett, Maggie C. U. Cheang

Summary: This study aimed to identify biomarkers for the response of ER+/HER2+ breast cancers to AI treatment. The results showed that HER2-E is a standardized biomarker associated with poor response to AI and worse prognosis in ER+/HER2+ breast cancers. HRD, TP53 mutational score, and immune-tumor tolerance are predictive biomarkers for poor response to AI. Additionally, new molecular subtypes identify non-HER2-E tumors that do not respond to AI and have an increased risk of relapse.

EBIOMEDICINE (2022)

Add to Collection

Editorial Material Oncology

Immune Checkpoint Blockade in HER2-Positive Breast Cancer: What Role in Early Disease Setting?

Cinzia Solinas, Debora Fumagalli, Maria Vittoria Dieci

Summary: This article discusses how to manipulate the anti- or pro-tumor immune response in early stage HER2-positive breast cancer patients through immune checkpoint blockade, and the potential benefits and fatal drawbacks of this strategy.

CANCERS (2021)

Add to Collection

Article Oncology

Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer

Gaia Griguolo, Maria Vittoria Dieci, Laia Pare, Federica Miglietta, Daniele Giulio Generali, Antonio Frassoldati, Luigi Cavanna, Giancarlo Bisagni, Federico Piacentini, Enrico Tagliafico, Katia Cagossi, Guido Ficarra, Aleix Prat, Pierfranco Conte, Valentina Guarneri

Summary: The study revealed differences in immune infiltration between hormone receptor positive and HER2 negative breast cancer subtypes, with non-luminal tumors showing higher levels of tumor-infiltrating lymphocytes and a more proinflammatory antitumor immune infiltrate composition compared to luminal tumors.

NPJ BREAST CANCER (2021)

Add to Collection

Article Immunology

Immune microenvironment dynamics of HER2 overexpressing breast cancer under dual anti-HER2 blockade

Sofia Batalha, Catarina Monteiro Gomes, Catarina Brito

Summary: This study presents a unique human 3D model for studying the immune effects of anti-HER2 biologicals, which can be used to test novel therapy regimens and improve anti-tumor immune function.

FRONTIERS IN IMMUNOLOGY (2023)

Add to Collection

Article Multidisciplinary Sciences

The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer

Yelena Y. Janjigian, Akihito Kawazoe, Patricio Yanez, Ning Li, Sara Lonardi, Oleksii Kolesnik, Olga Barajas, Yuxian Bai, Lin Shen, Yong Tang, Lucjan S. Wyrwicz, Jianming Xu, Kohei Shitara, Shukui Qin, Eric Van Cutsem, Josep Tabernero, Lie Li, Sukrut Shah, Pooja Bhagia, Hyun Cheol Chung

Summary: The study results demonstrate that adding pembrolizumab to trastuzumab and chemotherapy significantly reduces tumor size, induces complete responses in some patients, and improves objective response rate in HER2-positive gastric or gastro-oesophageal junction adenocarcinoma.

NATURE (2021)

Add to Collection

Review Oncology

Immunotherapies against HER2-Positive Breast Cancer

Santiago Duro-Sanchez, Macarena Roman Alonso, Joaquin Arribas

Summary: A variety of treatments are available for HER2-positive breast cancer, but resistance to these therapies is common and associated with poor prognosis. Immunotherapeutic approaches are being explored to eradicate tumor cells and prevent relapse and progression. This review discusses the different immunotherapeutic strategies being tested and their potential benefits for HER2-positive breast cancer.

CANCERS (2023)

Add to Collection

Article Oncology

Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node-positive, HER2-positive breast cancer

Chihwan Cha, Sung Gwe Ahn, Dooreh Kim, Janghee Lee, Soeun Park, Soong June Bae, Jee Ye Kim, Hyung Seok Park, Seho Park, Seung Il Kim, Byeong-Woo Park, Joon Jeong

Summary: Adding pertuzumab to chemotherapy increased the axillary pathological complete response (pCR) rate in patients with clinically node-positive, HER2-positive breast cancer, while dual HER2 blockade did not elevate the axillary response. Breast pCR could be a strong predictor for axillary pCR in clinically node-positive patients treated with HER2-targeting therapy.

INTERNATIONAL JOURNAL OF CANCER (2021)

Add to Collection

Review Oncology

Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer

Claudette Falato, Francesco Schettini, Tomas Pascual, Fara Braso-Maristany, Aleix Prat

Summary: Traditionally, breast cancer classification has relied on the expression of immunohistochemical bio-markers available in clinical practice. However, intrinsic molecular subtypes based on gene expression have been identified and show different characteristics compared to IHC-based subgroups. Hormone receptor-positive tumors can demonstrate non-luminal biology, which has prognostic value and impacts sensitivity to treatment. Genomic instability, cell plasticity, treatment selective pressure, and tumor microenvironment all contribute to the diversity observed between primary and metastatic breast cancer. This review focuses on hormone receptor-positive/HER2-negative advanced breast cancer and discusses the distribution and clinical behavior of intrinsic subtypes, as well as ongoing clinical trials investigating their predictive and prognostic value for routine care.

CANCER TREATMENT REVIEWS (2023)

Add to Collection

Article Oncology

HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1

Fara Braso-Maristany, Gaia Griguolo, Nuria Chic, Tomas Pascual, Laia Pare, Julia Maues, Patricia Galvan, Maria Vittoria Dieci, Federica Miglietta, Tommaso Giarratano, Olga Martinez-Saez, Mercedes Marin-Aguilera, Francesco Schettini, Benedetta Conte, Laura Angelats, Maria Vidal, Barbara Adamo, Montserrat Munoz, Esther Sanfeliu, Blanca Gonzalez, Ana Vivancos, Patricia Villagrasa, Joel S. Parker, Charles M. Perou, PierFranco Conte, Aleix Prat, Valentina Guarneri

Summary: This study evaluated the association between ERBB2 mRNA expression levels and response and survival following T-DM1 treatment. The results showed that ERBB2 mRNA expression levels were associated with better survival and treatment response.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2023)

Add to Collection

Article Oncology

Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials

Aranzazu Fernandez-Martinez, Tomas Pascual, Baljit Singh, Paolo Nuciforo, Naim U. Rashid, Karla Ballman, Jordan D. Campbell, Katherine A. Hoadley, Patricia A. Spears, Laia Pare, Fara Braso-Maristany, Nuria Chic, Ian Krop, Ann Partridge, Javier Cortes, Antonio Llombart-Cussac, Aleix Prat, Charles M. Perou, Lisa A. Carey

Summary: Assessment of tumor-infiltrating lymphocytes (TILs) and immune-related gene expression signatures can predict better treatment outcomes in patients with early-stage ERBB2/HER2-positive breast cancer. However, the combined prognostic value of these immune activation measures is not known.

JAMA ONCOLOGY (2023)

Add to Collection

Article Oncology

Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis

Susana L. Garcia-Recio, Toshinori J. Hinoue, Gregory L. C. Wheeler, Benjamin J. Kelly, Ana C. A. Garrido-Castro, Tomas Pascual, Aguirre A. M. De Cubas, Youli B. Xia, Brooke M. Felsheim, Marni B. McClure, Andrei A. Rajkovic, Ezgi Karaesmen, Markia A. Smith, Cheng E. Fan, Paula I. Gonzalez J. Ericsson, Melinda E. Sanders, Chad J. Creighton, Jay T. Bowen, Kristen Leraas, Robyn T. Burns, Sara Coppens, Amy L. Wheless, Salma S. Rezk, Amy L. K. Garrett, Joel S. Parker, Kelly K. H. Foy, Hui Shen, Ben H. Park, Ian Krop, Carey F. Anders, Julie Gastier-Foster, Mothaffar F. U. Rimawi, Rita Nanda, Nancy U. Lin, Claudine Isaacs, P. Kelly J. Marcom, Anna Maria Storniolo, Fergus J. Couch, Uma Chandran, Michael Davis, Jonathan C. Silverstein, Alexander G. Ropelewski, Minetta C. Liu, Susan G. L. Hilsenbeck, Larry Norton, Andrea L. C. Richardson, W. Fraser E. Symmans, Antonio C. A. Wolff, Nancy E. V. Davidson, Lisa A. M. Carey, Adrian V. A. Lee, Justin M. W. Balko, Katherine A. R. Hoadley, Peter W. A. Laird, Elaine R. A. Mardis, Tari A. A. King, Charles M. AURORA US Network, Charles M. Perou

Summary: The AURORA US Metastasis Project aimed to identify molecular features associated with metastasis in breast cancer. By analyzing the samples from 55 females with metastatic breast cancer, changes in gene expression subtypes and DNA clonality shifts were observed. Downregulation of estrogen receptor (ER)-mediated cell-cell adhesion genes through DNA methylation mechanisms was observed in metastases. Differences in the tumor microenvironment and immune cell infiltrates were also found in different breast cancer subtypes, providing implications for targeted therapies.

NATURE CANCER (2023)

Add to Collection

Article Oncology

Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of- opportunity SOLTI TOT-HER3 pre-operative study

M. Oliveira, C. Falato, J. M. Cejalvo, M. Margeli Vila, P. Tolosa, F. J. Salvador-Bo, J. Cruz, M. Arumi, A. M. Luna, J. A. Guerra, M. Vidal, O. Martinez-Saez, L. Pare, B. Gonzalez-Farre, E. Sanfeliu, E. Ciruelos, M. Espinosa-Bravo, S. Pernas, Y. Izarzugaza, S. Esker, P. -D Fan, P. Parul, A. Santhanagopal, D. Sellami, G. Villacampa, J. M. Ferrero-Cafiero, T. Pascual, A. Prat

Summary: This study aimed to evaluate the biological and clinical activity of HER3-DXd in patients with early breast cancer. The results showed that a single dose of HER3-DXd could increase immune infiltration, suppress proliferation, and had a good safety profile. Therefore, further research on HER3-DXd in early breast cancer treatment is warranted.

ANNALS OF ONCOLOGY (2023)

Add to Collection

Article Oncology

Nodal positivity and systemic therapy among patients with clinical T1-T2N0 human epidermal growth factor receptor-positive breast cancer: Results from two international cohorts

Anna Weiss, Olga Martinez-Saez, Adrienne G. Waks, Alison Laws, Monica McGrath, Paolo Tarantino, Leah Portnow, Eric Winer, Maria Rey, Marta Tapia, Aleix Prat, Ann H. Partridge, Sara M. Tolaney, Juan M. Cejalvo, Elizabeth A. Mittendorf, Tari A. King

Summary: This study evaluated the rates of pathologic nodal disease in patients with cT1-cT2N0M0 HER2-positive breast cancer who underwent upfront surgery or neoadjuvant chemotherapy. The results showed that approximately 20% of patients who underwent upfront surgery were pN-positive, and the rate increased to 25% for those with cT1c tumors. These findings suggest the need for further investigation into the use of routine axillary imaging in HER2-positive breast cancer patients.

CANCER (2023)

Add to Collection

Correction Oncology

Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study (Jan, 10.1007/s00262-022-03360-9, 2023)

Javier Garcia-Corbacho, Alberto Indacochea, Azucena E. Gonzalez Navarro, Ivan Victoria, Debora Moreno, David Pesantez, Laura Angelats, Andrea Modrego-Sanchez, Esther Sanfeliu, Oleguer Castillo, Paula Blasco, Laura Mezquita, Nuria Vinolas, Miquel Nogue, Patricia Galvan, Barbara Adamo, Neus Baste, Tamara Sauri, Manel Juan, Aleix Prat, Francesco Schettini

CANCER IMMUNOLOGY IMMUNOTHERAPY (2023)

Add to Collection

Article Oncology

A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+Breast Cancer

Jamunarani Veeraraghavan, Carolina Gutierrez, Carmine De Angelis, Robert Davis, Tao Wang, Tomas Pascual, Pier Selenica, Katherine Sanchez, Hiroaki Nitta, Monesh Kapadia, Anne C. Pavlick, Patricia Galvan, Brent Rexer, Andres Forero-Torres, Rita Nanda, Anna M. Storniolo, Ian E. Krop, Matthew P. Goetz, Julie R. Nangia, Antonio C. Wolff, Britta Weigelt, Jorge S. Reis-Filho, Susan G. Hilsenbeck, Aleix Prat, C. Kent Osborne, Rachel Schiff, Mothaffar F. Rimawi

Summary: The study aims to explore a multiparameter classifier to identify HER2+ breast cancer patients who can benefit from reducing chemotherapy. By analyzing samples from two clinical trials, the study found that the classifier can accurately predict the pathologic complete response rate to anti-HER2 therapy, thereby guiding treatment decisions.

CLINICAL CANCER RESEARCH (2023)

Add to Collection

Review Oncology

Landscape of neoadjuvant therapy in HER2-positive breast cancer: a systematic review and network meta-analysis

Guillermo Villacampa, Alexios Matikas, Mafalda Oliveira, Aleix Prat, Tomas Pascual, Andri Papakonstantinou

Summary: This study aimed to determine the optimal neoadjuvant regimen for HER2-positive breast cancer and if anthracyclines could be excluded. The results showed that dual anti-HER2 therapy with pertuzumab or tyrosine kinase inhibitors combined with chemotherapy had significantly better outcomes in terms of pCR, EFS, and OS compared to trastuzumab and chemotherapy. However, it was also associated with a higher risk of cardiotoxicity. Anthracycline-based chemotherapy was not superior to non-anthracycline-based chemotherapy. Addition of carboplatin in anthracycline-free regimens showed better efficacy outcomes. Therefore, dual HER2 blockade with chemotherapy, preferably excluding anthracyclines and using carboplatin, is recommended as neoadjuvant therapy for HER2-positive breast cancer.

EUROPEAN JOURNAL OF CANCER (2023)

Add to Collection

Letter Oncology

Reply to Bertucci, De Nonneville, and Finetti

Fara Braso-Maristany, Aleix Prat

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2023)

Add to Collection

Article Oncology

PROCURE European consensus on breast cancer multigene signatures in early breast cancer management

Giuseppe Curigliano, Fatima Cardoso, Michael Gnant, Nadia Harbeck, Judy King, Anne-Vibeke Laenkholm, Frederique Penault-Llorca, Aleix Prat

Summary: Breast cancer multigene signatures (BCMS) have changed the management of early-stage breast cancer (eBC) by providing prognostic information and helping select patients for adjuvant chemotherapy. However, there is limited knowledge on the current usage and perceived utility of BCMS in clinical practice. A two-round Delphi survey involving 133 breast cancer experts from 11 European countries revealed that BCMS are widely used to assess risk of recurrence and select patients for adjuvant chemotherapy, but consensus is lacking regarding their utility in selecting specific chemotherapy types. There are also discrepancies between recommended usage and actual usage, with some profiles lacking supporting evidence. The study suggests the need for physician education initiatives to ensure proper use and interpretation of BCMS, ultimately improving management of eBC patients.

NPJ BREAST CANCER (2023)

Add to Collection

Article Oncology

Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancer

Maria Vittoria Dieci, Pierfranco Conte, Giancarlo Bisagni, Stefania Bartolini, Antonio Frassoldati, Daniele Generali, Federico Piacentini, Gaia Griguolo, Enrico Tagliafico, Fara Braso Maristany, Nuria Chic, Laia Pare, Federica Miglietta, Roberto Vicini, Roberto D'Amico, Sara Balduzzi, Aleix Prat, Valentina Guarneri

Summary: The integration of intrinsic molecular subtypes with stage or HER2DX risk score can predict site-specific metastatic risk in HER2-positive breast cancer, potentially impacting personalized surveillance and preventing site-specific recurrence in clinical trials.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2023)

Add to Collection

Meeting Abstract Medicine, Research & Experimental

Genome-Wide Analysis of the DNA Methylation Profile Reveals a Prognostic CpG Island Methylator Phenotype in Advanced Breast Tumors

Eva Musulen, Aleix Noguera-Castells, Patricia Villagrasa, Jordi Canes, Tomas Pascual, Patricia Galvan, Aleix Prat, Eva Ciruelos, Sonia Pernas, Manel Esteller

LABORATORY INVESTIGATION (2023)

Add to Collection

Article Oncology

Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial

Sara M. Tolaney, Paolo Tarantino, Noah Graham, Nabihah Tayob, Laia Pare, Guillermo Villacampa, Chau Dang, Denise A. Yardley, Beverly Moy, P. Kelly Marcom, Kathy S. Albain, Hope S. Rugo, Matthew J. Ellis, Iuliana Shapira, Antonio C. Wolff, Lisa A. Carey, Romualdo Barroso-Sousa, Patricia Villagrasa, Michelle DeMeo, Molly DiLullo, Jorge Gomez Tejeda Zanudo, Jakob Weiss, Nikhil Wagle, Ann H. Partridge, Adrienne G. Waks, Clifford A. Hudis, Ian E. Krop, Harold J. Burstein, Aleix Prat, Eric P. Winer

Summary: This study reports the long-term outcomes of patients with small, node-negative, HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab, and establishes potential biomarkers to predict prognosis. The results indicate that adjuvant paclitaxel and trastuzumab is a reasonable treatment standard for this population, and the HER2DX genomic tool might help refine the prognosis.

LANCET ONCOLOGY (2023)

Add to Collection

Article Oncology

Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine plus pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE)

Sanne L. de Haas, Dennis J. Slamon, Miguel Martin, Michael F. Press, Gail D. Lewis, Chiara Lambertini, Aleix Prat, Vanesa Lopez-Valverde, Thomas Boulet, Sara A. Hurvitz

Summary: The KRISTINE study investigated the association of biomarkers with clinical outcomes in HER2-positive breast cancer patients. Although no specific subgroup of patients benefited from neoadjuvant T-DM1 + P versus TCH + P, the data revealed that patients with higher HER2 amplification/expression and immune marker levels had improved response irrespective of treatment arm.

BREAST CANCER RESEARCH (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.